Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (02566) disclosed a Next Day Disclosure Return stating that, as of 06 February 2026, the company had 105,594,985 issued shares (excluding treasury shares) and 3,501,800 treasury shares.

On 09 February 2026, the company repurchased 60,800 shares at prices ranging from HKD 9.81 to HKD 10 per share, with a total consideration of approximately HKD 605,939.97. Following this repurchase, the number of treasury shares increased to 3,562,600, while the number of issued shares (excluding treasury shares) decreased to 105,534,185. The overall total number of issued shares remains 109,096,785.

According to the announcement, the repurchase mandate was granted on 11 June 2025, authorizing repurchases of up to 10,909,678 shares. The company also noted a moratorium period extending through 11 March 2026, during which no new issuance of shares or sale or transfer of treasury shares may occur without prior approval of the Hong Kong Stock Exchange.